Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations (OPS II)
A Randomized, Double-blind, Placebo Controlled Trial of Testosterone Undecanoate for Optimizing Physical and Cognitive Performance During Military Operations (OPS II)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men aged 18-35 years
- Ability to understand verbal or written instructions/testing materials in English
- Physically active (as determined by accelerometry and review of a physical activity log)
- Not taking any prescription medications and/or willing to refrain from all medication use prior to and throughout the entire study period, unless provided/approved by the study physician
- Willing to refrain from alcohol, smoking, e-cigarettes or use of any nicotine product, caffeine, and dietary supplement use throughout the entire study period
- Willing to live on the Pennington Biomedical Research Center inpatient unit for 20 consecutive days
- Meets age-specific US Army body composition standards according to Army Regulation 600-9, which includes estimates of percent body fat based on height, weight, and circumference measures (neck and waist)
- Total testosterone concentration is within the normal physiological range (300-1,000 ng/dL)
Exclusion Criteria:
- Musculoskeletal injuries that compromise exercise capability
- Diagnosed cardiometabolic disorders (i.e., hypertension, hyperlipidemia, kidney disease, diabetes, etc.)
- Allergies or intolerance to foods, vegetarian practices, or history of complications with lidocaine
- Anabolic steroid, human growth hormone, or nutritional testosterone precursor-like supplement use within the past 6 months
- Will not refrain from smoking (any nicotine product), alcohol, caffeine, or any other dietary supplement during the study
- Adults unable to consent
- Women
- Prisoners
- Sedentary or engages in insufficient quantities of physical activity per week (aerobic and/or resistance training as determined by accelerometry and review of a physical activity log)
- Exceeds age-specific US Army body composition standards according to Army Regulation 600-9
- Previous history of kidney stones unless otherwise approved by the medical investigator
- Systolic blood pressure > 150 or diastolic blood pressure > 95 mmHg
- Previous history of breast or prostate cancer
- Previous history of Chronic Obstructive Pulmonary Disease or Obstructive Sleep Apnea
- Prostate-Specific Antigen (PSA) > 3ng/ml, Hematocrit > 50%, or positive urine drug screening
- Based on the investigative team's clinical judgment, a subject may not be appropriate for participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
single intramuscular injection of 750 mg sesame oil solution on Day 8
|
single intramuscular injection of 750 mg sesame oil solution
|
|
Experimental: Testosterone
single intramuscular injection of 750 mg testosterone undecanoate on Day 8
|
single intramuscular injection of 750 mg testosterone undecanoate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Load Carriage Time
Time Frame: Day 5 (Phase 1), Day 26 (Phase 2), Day 47 (Phase 3)
|
A load carriage time trial (a militarily relevant aerobic performance assessment) was conducted near the end of each study phase to assess aerobic performance.
|
Day 5 (Phase 1), Day 26 (Phase 2), Day 47 (Phase 3)
|
|
Vertical Jump Height
Time Frame: Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
|
Lower-body peak power was assessed near the end of each phase using a vertical jump test.
|
Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
|
|
Total Mass Lifted
Time Frame: Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
|
A 3-repetition maximum deadlift assessed muscular strength, endurance, and explosive power near the end of each study phase.
|
Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
|
|
Wingate Peak Power
Time Frame: Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
|
Anaerobic capacity was assessed using a Wingate anaerobic cycle test near the end of each study phase.
|
Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
|
|
Peak Aerobic Capacity
Time Frame: Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
|
Peak aerobic capacity was measured via treadmill VO2peak near the end of each study phase.
|
Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Composition
Time Frame: Day 7 (Phase 1), Day 28 (Phase 2), Day 49 (Phase 3)
|
A four-compartment (4C) model factoring in body mass, body volume, total body water, and bone mineral content was used to calculate fat-free body mass and fat mass at the end of each study phase.
|
Day 7 (Phase 1), Day 28 (Phase 2), Day 49 (Phase 3)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jennifer C Rood, PhD, Pennington Biomedical Research Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PBRC 2019-017
- W81XWH19C0162 (Other Grant/Funding Number: USA MED RESEARCH ACQ ACTIVITY)
- W81XWH19D0010 (Other Grant/Funding Number: USA MED RESEARCH ACQ ACTIVITY)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.